CU06-1004 enhances vascular integrity and improves cardiac remodeling by suppressing edema and inflammation in myocardial ischemia–reperfusion injury
2
조회
0
다운로드
1
인용
0
참고문헌
초록
Ischemia–reperfusion (I/R) injury accelerates the cardiomyocytes (CMs) death by oxidative stress, and thereby deteriorates cardiac function. There has been a paradigm shift in the therapeutic perspective more towards the prevention or amelioration of damage caused by reperfusion. Cardiac microvascular endothelial cells (CMECs) are more vulnerable to reperfusion injury and play the crucial roles more than CMs in the pathological process of early I/R injury. In this study, we investigate that CU06-1004, as a vascular leakage blocker, can improve cardiac function by inhibiting CMEC’s hyperpermeability and subsequently reducing the neutrophil’s plugging and infiltration in infarcted hearts. CU06-1004 was delivered intravenously 5 min before reperfusion and the rats were randomly divided into three groups: (1) vehicle, (2) low-CU06-1004 (1 mg/kg, twice at 24 h intervals), and (3) high-CU06-1004 (5 mg/kg, once before reperfusion). CU06-1004 treatment reduced necrotic size and cardiac edema by enhancing vascular integrity, as demonstrated by the presence of intact junction proteins on CMECs and surrounding pericytes in early I/R injury. It also decreased the expression of vascular cell adhesion molecule 1 (VCAM-1) on CMECs, resulting in reduced infiltration of neutrophils and macrophages. Echocardiography showed that the CU06-1004 treatment significantly improved cardiac function compared with the vehicle group. Interestingly, single high-dose treatment with CU06-1004 provided a greater functional improvement than repetitive low-dose treatment until 8 weeks post I/R. These findings demonstrate that CU06-1004 enhances vascular integrity and improves cardiac function by preventing lethal myocardial I/R injury. It can provide a promising therapeutic option, as potential adjunctive therapy to current reperfusion strategies.
Abstract
Ischemia–reperfusion (I/R) injury accelerates the cardiomyocytes (CMs) death by oxidative stress, and thereby deteriorates cardiac function. There has been a paradigm shift in the therapeutic perspective more towards the prevention or amelioration of damage caused by reperfusion. Cardiac microvascular endothelial cells (CMECs) are more vulnerable to reperfusion injury and play the crucial roles more than CMs in the pathological process of early I/R injury. In this study, we investigate that CU06-1004, as a vascular leakage blocker, can improve cardiac function by inhibiting CMEC’s hyperpermeability and subsequently reducing the neutrophil’s plugging and infiltration in infarcted hearts. CU06-1004 was delivered intravenously 5 min before reperfusion and the rats were randomly divided into three groups: (1) vehicle, (2) low-CU06-1004 (1 mg/kg, twice at 24 h intervals), and (3) high-CU06-1004 (5 mg/kg, once before reperfusion). CU06-1004 treatment reduced necrotic size and cardiac edema by enhancing vascular integrity, as demonstrated by the presence of intact junction proteins on CMECs and surrounding pericytes in early I/R injury. It also decreased the expression of vascular cell adhesion molecule 1 (VCAM-1) on CMECs, resulting in reduced infiltration of neutrophils and macrophages. Echocardiography showed that the CU06-1004 treatment significantly improved cardiac function compared with the vehicle group. Interestingly, single high-dose treatment with CU06-1004 provided a greater functional improvement than repetitive low-dose treatment until 8 weeks post I/R. These findings demonstrate that CU06-1004 enhances vascular integrity and improves cardiac function by preventing lethal myocardial I/R injury. It can provide a promising therapeutic option, as potential adjunctive therapy to current reperfusion strategies.
참고문헌 (42)
- Anderson, J. L., "Acute myocardial infarction", N. Engl. J. Med, 376, pp.2053~2064 (2017)
- Ibáñez, B., "Evolving therapies for myocardial ischemia", reperfusion injury, 2015, pp.65, 1454~1471
- Neri, M., "Ischemia", reperfusion injury following acute myocardial infarction : a critical issue for clinicians and forensic pathologists, 2017, pp.2017, 7018393~
- Mancini, G. B., "Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study", Circulation, 94, pp.258~265 (1996)
- Heitzer, T., "Antioxidant vitamin C improves endothelial dysfunction in chronic smokers", Circulation, 94, pp.6~9 (1996)
- Barrios, V., "N-acetylcysteine potentiates the antihypertensive effect of ACE inhibitors in hypertensive patients", Blood Pressure, 11, pp.235~239 (2002)
- Zepeda, R. J., "Effect of carvedilol and nebivolol on oxidative stress-related parameters and endothelial function in patients with essential hypertension", Basic Clin. Pharmacol. Toxicol, 111, pp.309~316 (2012)
- Wilkerson, B. A., "The role of sphingosine-1-phosphate in endothelial barrier function", Biochim. Biophys. Acta, 1841, pp.1403~1412 (2014)
- Ceconi, C., "Noradrenaline, atrial natriuretic peptide, bombesin and neurotensin in myocardium and blood of rats in congestive cardiac failure", Cardiovasc. Res, 23, pp.674~682 (1989)
- Singhal, A. K., "Role of endothelial cells in myocardial ischemia-reperfusion injury", Vasc. Dis. Prev, 7, pp.1~14 (2010)
- Zhang, H., "Sac-1004, a vascular leakage blocker, reduces cerebral ischemia—reperfusion injury by suppressing blood–brain barrier disruption and inflammation", J. Neuroinflammation, 14, pp.122~ (2017)
- Maharjan, S., "Sac-1004, a novel vascular leakage blocker, enhances endothelial barrier through the cAMP", Rac, Biochem. Biophys. Res. Commun, pp.2013, 435[DOI]
- Agrawal, V., "Direct endothelial junction restoration results in significant tumor vascular normalization and metastasis inhibition in mice", Oncotarget, 5, pp.2761~2777 (2014)
- Colliva, A., "Endothelial cell-cardiomyocyte crosstalk in heart development and disease", J. Physiol, 598, pp.2923~2939 (2020)
- Scarabelli, T., "Apoptosis of endothelial cells precedes myocyte cell apoptosis in ischemia", reperfusion injury, 2001, pp.104, 253~256
- Chen, G., "Cardiomyocyte-derived small extracellular vesicles can signal eNOS activation in cardiac microvascular endothelial cells to protect against Ischemia", Reperfusion injury, 2020, pp.10, 11754~11774
- Carnicer, R., "Nitric oxide synthases in heart failure", Antioxid. Redox Signal, 18, pp.1078~1099 (2013)
- Khairoun, M., "Renal ischemia-reperfusion induces a dysbalance of angiopoietins, accompanied by proliferation of pericytes and fibrosis", Am. J. Physiol. Ren. Physiol, 305, pp.F901~F910 (2013)
- Frangogiannis, N. G., "Inflammation in cardiac injury, repair and regeneration", Curr. Opin. Cardiol, 30, pp.240~245 (2015)
- Chen, L., "Inflammatory responses and inflammation-associated diseases in organs", Oncotarget, 9, pp.7204~7218 (2018)
- Frangogiannis, N. G., "The inflammatory response in myocardial injury, repair, and remodelling", Nat. Rev. Cardiol, 11, pp.255~265 (2014)
- Toldo, S., "Inflammasome, pyroptosis, and cytokines in myocardial ischemia-reperfusion injury", Am. J. Physiol. Heart Circ. Physiol, 315, pp.H1553~h1568 (2018)
- Aslam, M., "Hypoxia-reoxygenation-induced endothelial barrier failure : role of RhoA, Rac1 and myosin light chain kinase", J. Physiol, 591, pp.461~473 (2013)
- Millar, T. M., "ROS generation in endothelial hypoxia and reoxygenation stimulates MAP kinase signaling and kinase-dependent neutrophil recruitment", Free Radic. Biol. Med, 42, pp.1165~1177 (2007)
- Yang, Q., "Cellular and molecular mechanisms of endothelial ischemia", reperfusion injury : perspectives and implications for postischemic myocardial protection, 2016, pp.8, 765~777
- Hadi, H. A., "Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome", Vasc. Health Risk Manag, 1, pp.183~198 (2005)
- Hausenloy, D. J., "Novel targets and future strategies for acute cardioprotection:position paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart", Cardiovasc. Res, 113, pp.564~585 (2017)
- Kitakaze, M., "Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials", Lancet, 370, pp.1483~1493 (2007)
- Kyhl, K., "A post hoc analysis of long-term prognosis after exenatide treatment in patients with ST-segment elevation myocardial infarction", EuroIntervention, 12, pp.449~455 (2016)
- Roolvink, V., "Early intravenous beta-blockers in patients with ST-segment elevation myocardial infarction before primary percutaneous coronary intervention", J. Am. Coll. Cardiol, 67, pp.2705~2715 (2016)
- Ottani, F., "Cyclosporine A in reperfused myocardial infarction : the multicenter, controlled, open-label CYCLE trial", J. Am. Coll. Cardiol, 67, pp.365~374 (2016)
- Gaboury, J. P., "Molecular mechanisms involved in superoxide-induced leukocyte-endothelial cell interactions in vivo", Am. J. Physiol, 266, pp.H637~H642 (1994)
- Patel, K. D., "Oxygen radicals induce human endothelial cells to express GMP-140 and bind neutrophils", J. Cell Biol, 112, pp.749~759 (1991)
- Lucchesi, B. R., "Complement activation, neutrophils, and oxygen radicals in reperfusion injury", Stroke, 24, pp.I41~I47 (1993)[DOI]
- Brutsaert, D. L., "Cardiac endothelial-myocardial signaling: its role in cardiac growth, contractile performance, and rhythmicity", Physiol. Rev, 83, pp.59~115 (2003)
- Brutsaert, D. L., "Cardiac endothelium and myocardial function1", Cardiovasc. Res, 38, pp.281~290 (1998)
- Davidson, S. M., "Endothelial cells release cardioprotective exosomes that may contribute to ischaemic preconditioning", Sci. Rep, 8, pp.15885~ (2018)
- Leucker, T. M., "Impairment of endothelial-myocardial interaction increases the susceptibility of cardiomyocytes to ischemia", reperfusion injury, 2013, pp.8, e70088~
- Kongpol, K., "Endothelial-cellderived human secretory leukocyte protease inhibitor(SLPI)protects cardiomyocytes against ischemia", reperfusion injury, 2019, pp.9, 678~
- Kuramochi, Y., "Cardiac endothelial cells regulate reactive oxygen speciesinduced cardiomyocyte apoptosis through neuregulin-1beta", erbB4 signaling, 2004, pp.279, 51141~51147
- Bonaventura, J., "NO and superoxide: opposite ends of the seesaw in cardiac contractility", Proc. Natl Acad. Sci. USA, 101, pp.16403~16404 (2004)
- Kloner, R. A., "No-reflow phenomenon : maintaining vascular integrity", J. Cardiovasc. Pharmacol. Ther, 16, pp.244~250 (2011)